Body Psoriasis

Roflumilast foam 0.3% improved patient-reported outcomes in scalp and body psoriasis, according to a poster presentation at the Fall Clinical Dermatology Conference.

The FDA has accepted Arcutis Biotherapeutics’ supplemental new drug application for Zoryve foam 0.3% for the treatment of scalp and body psoriasis in adults and adolescents aged 12 years and older, the company announced in a press release.

Arcutis has submitted a supplemental new drug application for Zoryve foam 0.3% for the treatment of scalp and body psoriasis in adults and adolescents aged 12 years and older, according to a company press release.